Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients

NCT02683083 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Breast Cancer

Interventions

BIOLOGICAL: [131I]-SGMIB Anti-HER2 VHH1

Sponsor

Precirix